Amgen sees no bone safety concerns around experimental obesity drug
Amgen sees no bone safety concerns around experimental obesity drug Source link
Amgen stock falls on weight loss drug’s bone density loss data
Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the additional data suggests a new potential safety risk tied to the drug. But others said the share move was an overreaction, and that more data on a larger group of patients is needed. Amgen did not immediately respond to
Recent News
-
-
-
El Salvador Is Getting Its First Tokenized U.S. Treasuries Offering
November 20, 2024 -
Super Micro Options Imply More Volatility for the Stock
November 20, 2024 -
MSF charity halts work in Port-au-Prince over attacks
November 20, 2024 -
Mike Tyson, Jake Paul fight was most-streamed sports event: Netflix
November 20, 2024 -
-
-
-
-
BTC Hits New ATH, GOAT and BONK Rise 8-13%
November 20, 2024 -
-
Kremlin Says Russia-US Hotline to Deflate Crisis Not in Use
November 20, 2024 -
Comcast to spin off NBCUniversal TV networks
November 20, 2024 -
Frontier Airlines is adding 16 new routes. Here’s where they are.
November 20, 2024 -
-
-
-
-
